Boehringer Ingelheim Venture Fund
VC Fund
Ingelheim Am Rhein, Germany
Boehringer Ingelheim Venture Fund is a VC fund in Ingelheim Am Rhein focused on Biotechnology and Health Care. Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies.
- Total investments:
- 108
- Last investment:
- Lead investor:
- 48%
- Fund size:
- $250M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Boehringer Ingelheim Venture Fund invests in
Stages Boehringer Ingelheim Venture Fund invests in
Countries Boehringer Ingelheim Venture Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.8M–$20M
- Series A
- $3.8M–$34M
- Series B
- $11M–$50M
Investment Focus
Industry
- Biotechnology 49 (45%)
- Health Care 26 (24%)
- Therapeutics 24 (22%)
- Medical 19 (18%)
- Life Science 7 (6%)
Stage
- Series A 35 (32%)
- Series B 21 (19%)
- Seed 20 (19%)
- Series C 7 (6%)
- Venture - Series Unknown 3 (3%)
Country
- United States 16 (15%)
- Germany 12 (11%)
- Switzerland 6 (6%)
- Belgium 4 (4%)
- China 3 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Debbie Lin
Executive Director
|
Executive Director | Total investments: 1 | Find email | |
Martin Heidecker
Managing Director
|
Managing Director | Total investments: 10 | Find email | |
Knut Elbers
Project Manager
|
Project Manager | Total investments: 3 | Find email | |
Oliver Reuss
Executive Director and Investment Manager
|
Executive Director and Investment Manager | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Cloverleaf Bio develops an RNA therapeutic platform for oncology. | $33M / Seed / Sep 08, 2026 | ||
| smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms. | Seed / Jun 30, 2026 | ||
| Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms. | $12.9M / Seed / Apr 29, 2026 | ||
| TECregen is a biotechnology company that develops thymus-rejuvenating biologics to restore immune function and T-cell responses. | $12.5M / Seed / Jan 08, 2026 | ||
| STRM.BIO specializes in the fields of biotechnology and life science. | $8M / Seed / Jan 07, 2026 | ||
| smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms. | $5.5M / Seed / Oct 22, 2025 | ||
| EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs. The company's pipeline includes robust scientific antibody programs for the treatment of hepatocellular carcinoma (Phase 1 ready) and chronic kidney disease with left ventricular hypertrophy (pre-clinical). | $24.6M / Seed / Jul 07, 2025 | ||
| ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections. | Seed / Jun 23, 2025 | ||
| Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts. | $45M / Series B / May 06, 2025 | ||
| Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time. | $18.2M / Series C / Mar 18, 2025 | ||
| See all 108 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Boehringer Ingelheim Venture Fund invest in?
Boehringer Ingelheim Venture Fund invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 108 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Boehringer Ingelheim Venture Fund's check size?
Boehringer Ingelheim Venture Fund typically joins rounds of $1.8M–$20M at Seed, $3.8M–$34M at Series A and $11M–$50M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Boehringer Ingelheim Venture Fund participates in.
How do I contact Boehringer Ingelheim Venture Fund?
Public channels for Boehringer Ingelheim Venture Fund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Boehringer Ingelheim Venture Fund?
The team at Boehringer Ingelheim Venture Fund includes Debbie Lin (Executive Director), Martin Heidecker (Managing Director) and Knut Elbers (Project Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
